Slide 1: Conference Call 9M 2022 Results
Conference Call 9M 2022 Results Joachim Kreuzburg, Rainer Lehmann Sartorius | Sartorius Stedim Biotech | October 19, 2022
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 3: Highlights
Highlights ▪ Double-digit growth of sales revenues and earnings in both divisions ▪ Healthy profitability based on positive scale effects, diluted by higher cost base and FX-related headwinds ▪ Fundamentally strong market impacted by rapid normalization of demand in bioprocessing domain ▪ Outlook fo
Slide 4: Acquisition of Albumedix further strengthens the portfolio for advanced therapies
Acquisition of Albumedix further strengthens the portfolio for advanced therapies Nottingham, UK Strategic rationale >100 employees ▪ Leader in the field of recombinant albumin, a critical component in the manufacture and formulation of innovative biopharmaceuticals GMP manufacturing ▪ Strengthens S
Slide 5: Agenda
Agenda Sartorius Group 9M 2022 results | FY 2022 guidance Sartorius Stedim Biotech Group 9M 2022 results | FY 2022 guidance Questions & Answers 5
Slide 6: Strong sales growth, margin close to high prior-year level
Sartorius Group Strong sales growth, margin close to high prior-year level Sartorius Group 9M 2021 9M 2022 in % in % cc1 in millions of € unless otherwise specified Sales revenue 2,526.9 3,112.9 +23.2 +16.6 Order intake 3,286.2 3,121.1 -5.0 -9.5 Underlying EBITDA2 866.4 1,051.5 +21.4 Underlying EBIT
Slide 7: Double-digit growth across all geographies; Americas growing the fastest
Sartorius Group Double-digit growth across all geographies; Americas growing the fastest Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +22.5% +10.4% +18.7% EMEA Americas ~ 37% ~ 36% 1,130.1 1,038.8 1,157.9 824.9 825.4 662.7 €3,112.9m Asia|Pacific 9M 2021 9
Slide 8: Bioprocess Solutions: Double-digit increase in sales revenue and earnings
Sartorius Group Bioprocess Solutions: Double-digit increase in sales revenue and earnings; order intake below exceptionally high prior-year figure Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions -14.4% cc +17.7% cc -10.3% +21.7% +24.3% 2,733.0 2,451.8
Slide 9: Lab Products & Services: Dynamic growth fueled by Bioanalytics business
Sartorius Group Lab Products & Services: Dynamic growth fueled by Bioanalytics business Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +14.6% cc +12.5% cc +19.8% +21.0% +19.0% 669.4 642.1 170.0 553.2 539.4 141.9 26.3% 26.5% 9M 2021 9M 2022 9M 2021 9M
Slide 10: Build-up of inventories reflected in cash flow
Sartorius Group Build-up of inventories reflected in cash flow Sartorius Group 9M 2021 9M 2022 in % in millions of € unless otherwise specified Underlying EBITDA 866.4 1,051.5 +21.4 ▪ Higher inventories to support supply security Extraordinary items -22.7 -26.1 -15.2 impact cash flow Financial resul
Slide 11: Robust financial key figures, influenced by recent Albumedix acquisition
Sartorius Group Robust financial key figures, influenced by recent Albumedix acquisition Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Dec. 31, Sep. 30, Sartorius Group 2,500 4.0 2021 2022 2,000 3.0 Equity ratio in % 30.2 35.4 1,500 2.0 1,000 Net debt in millions of € 1,732.7 2
Slide 12: Guidance 2022 specified for sales growth, profitability unchanged
Sartorius Group Guidance 2022 specified for sales growth, profitability unchanged, uncertainties remain high Specified guidance 2022 1 Sales revenue growth Underlying EBITDA margin lower half of range Sartorius Group ~34% ~15% - 19% thereof from acquisitions ~2pp lower half of range Bioprocess Solut
Slide 13: Agenda
Agenda Sartorius Group 9M 2022 results | FY 2022 guidance Sartorius Stedim Biotech Group 9M 2022 results | FY 2022 guidance Questions & Answers 13
Slide 14: Stedim Biotech: Double-digit increase in sales revenue and earnings
Sartorius Stedim Biotech Group Double-digit increase in sales revenue and earnings; order intake below exceptionally high prior-year figure Sartorius Stedim Biotech Group 9M 2021 9M 2022 in % in % cc1 in millions of € unless otherwise specified Sales revenue 2,108.8 2,602.7 +23.4 +17.0 Order intake
Slide 15: Double-digit growth across all regions; Americas growing the fastest
Sartorius Stedim Biotech Group Double-digit growth across all regions; Americas growing the fastest Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +22.7% +11.0% +19.7% EMEA Americas ~ 38% ~ 36% 927.3 989.6 884.1 €2,602.7m 677.8 685.8 546.9 Asia|Pacific ~ 26
Slide 16: Buildup of inventories reflected in cash flow
Sartorius Stedim Biotech Group Buildup of inventories reflected in cash flow Sartorius Stedim Biotech Group 9M 2021 9M 2022 in % in millions of € unless otherwise specified Underlying EBITDA 765.5 911.9 +19.1 ▪ Higher inventories to support supply security Extraordinary items -16.0 -13.4 +16.6 impac
Slide 17: Robust financial indicators; debt ratio remains low despite Albumedix acquisition
Sartorius Stedim Biotech Group Robust financial indicators; debt ratio remains low despite recent Albumedix acquisition Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA 1200 1.8 Dec. 31, Sep. 30, Sartorius Stedim Biotech Group 2021 2022 1000 1.5 800 1.2 Equity ratio in % 43.9 46.1
Slide 18: Guidance 2022 specified for sales growth, profitability unchanged
Sartorius Stedim Biotech Group Guidance 2022 specified for sales growth, profitability unchanged, uncertainties remain high Specified Guidance 20221 Sales revenue growth Underlying EBITDA margin lower half of range Sartorius Stedim Biotech Group ~15% - 19% >35% thereof from acquisitions ~2pp ▪ Coron
Slide 19: Questions & Answers
Questions & Answers 19